These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25153380)

  • 21. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
    Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
    Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
    Fuhrman-Luck RA; Loessner D; Clements JA
    EJIFCC; 2014 Oct; 25(3):269-81. PubMed ID: 27683474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kallikrein-related peptidases in cancers of gastrointestinal tract: an inside view of their role and clinical significance.
    Linardoutsos D; Gazouli M; Machairas A; Bramis I; Zografos GC
    J BUON; 2014; 19(1):53-9. PubMed ID: 24659643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
    Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
    J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies.
    Mavridis K; Scorilas A
    Future Oncol; 2010 Feb; 6(2):269-85. PubMed ID: 20146586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
    Avgeris M; Mavridis K; Scorilas A
    Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
    Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
    Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines.
    Shaw JL; Diamandis EP
    Biol Chem; 2008 Nov; 389(11):1409-19. PubMed ID: 19031603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of kallikrein-related peptidases in the skin - from physiology to diseases to therapeutic options.
    Fischer J; Meyer-Hoffert U
    Thromb Haemost; 2013 Sep; 110(3):442-9. PubMed ID: 23446429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers.
    Kontos CK; Scorilas A
    Clin Chem Lab Med; 2012 Nov; 50(11):1877-91. PubMed ID: 23093268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.
    Dorn J; Bayani J; Yousef GM; Yang F; Magdolen V; Kiechle M; Diamandis EP; Schmitt M
    Thromb Haemost; 2013 Sep; 110(3):408-22. PubMed ID: 23765253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
    Pasic MD; Olkhov E; Bapat B; Yousef GM
    Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
    Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
    Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
    Filippou PS; Karagiannis GS; Musrap N; Diamandis EP
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):277-91. PubMed ID: 26886390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
    Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
    Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
    Goettig P; Magdolen V; Brandstetter H
    Biochimie; 2010 Nov; 92(11):1546-67. PubMed ID: 20615447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interdependence of kallikrein-related peptidases in proteolytic networks.
    Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
    Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids.
    Oikonomopoulou K; Hansen KK; Baruch A; Hollenberg MD; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):747-56. PubMed ID: 18627291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology.
    Shaw JL; Diamandis EP
    Biol Chem; 2008 Jun; 389(6):681-8. PubMed ID: 18627298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
    White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
    Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.